MMP induction and inhibition in myocardial infarction

Research output: Contribution to journalReview article

98 Citations (Scopus)

Abstract

Short-term survival following a myocardial infarction (MI) has greatly improved, due in part to therapeutic interventions that restore blood flow and limit infarct size. The increased incidence of infarct-stimulated left ventricular (LV) remodeling that advances to congestive heart failure (CHF), however, is a significant long-term complication and a leading cause of mortality. Changes to ECM structure and function are primary components of LV remodeling and are precipitated by the early increase in infarct area collagen levels that replace necrotic myocytes and form a scar. ECM turnover is coordinated through the synthesis and degradation of ECM and non-ECM components, particularly the matrix metalloproteinases (MMP), a family of proteolytic enzymes that cleave ECM. MMFs have multiple roles in remodeling events that lead to LV dilation. The inhibition or targeted deletion of specific MMPs attenuates LV remodeling events post-MI. MMP inhibitors have been used in animal models to delineate LV remodeling mechanisms and to evaluate the pharmacologic potential of targeting the ECM to modify LV remodeling post-MI. This review summarizes the current knowledge and limitations of MMP inhibition in the post-MI myocardium.

Original languageEnglish (US)
Pages (from-to)7-19
Number of pages13
JournalHeart Failure Reviews
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Ventricular Remodeling
Matrix Metalloproteinases
Myocardial Infarction
Matrix Metalloproteinase Inhibitors
Muscle Cells
Cicatrix
Dilatation
Myocardium
Peptide Hydrolases
Collagen
Animal Models
Heart Failure
Mortality
Incidence

Keywords

  • Extracellular matrix
  • MMP inhibition
  • Matrix metalloproteinases
  • Myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

MMP induction and inhibition in myocardial infarction. / Lindsey, Merry L.

In: Heart Failure Reviews, Vol. 9, No. 1, 01.01.2004, p. 7-19.

Research output: Contribution to journalReview article

@article{205aee6069f64cb6aff82f0f4073d14b,
title = "MMP induction and inhibition in myocardial infarction",
abstract = "Short-term survival following a myocardial infarction (MI) has greatly improved, due in part to therapeutic interventions that restore blood flow and limit infarct size. The increased incidence of infarct-stimulated left ventricular (LV) remodeling that advances to congestive heart failure (CHF), however, is a significant long-term complication and a leading cause of mortality. Changes to ECM structure and function are primary components of LV remodeling and are precipitated by the early increase in infarct area collagen levels that replace necrotic myocytes and form a scar. ECM turnover is coordinated through the synthesis and degradation of ECM and non-ECM components, particularly the matrix metalloproteinases (MMP), a family of proteolytic enzymes that cleave ECM. MMFs have multiple roles in remodeling events that lead to LV dilation. The inhibition or targeted deletion of specific MMPs attenuates LV remodeling events post-MI. MMP inhibitors have been used in animal models to delineate LV remodeling mechanisms and to evaluate the pharmacologic potential of targeting the ECM to modify LV remodeling post-MI. This review summarizes the current knowledge and limitations of MMP inhibition in the post-MI myocardium.",
keywords = "Extracellular matrix, MMP inhibition, Matrix metalloproteinases, Myocardial infarction",
author = "Lindsey, {Merry L.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1023/B:HREV.0000011390.44039.b7",
language = "English (US)",
volume = "9",
pages = "7--19",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - MMP induction and inhibition in myocardial infarction

AU - Lindsey, Merry L.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Short-term survival following a myocardial infarction (MI) has greatly improved, due in part to therapeutic interventions that restore blood flow and limit infarct size. The increased incidence of infarct-stimulated left ventricular (LV) remodeling that advances to congestive heart failure (CHF), however, is a significant long-term complication and a leading cause of mortality. Changes to ECM structure and function are primary components of LV remodeling and are precipitated by the early increase in infarct area collagen levels that replace necrotic myocytes and form a scar. ECM turnover is coordinated through the synthesis and degradation of ECM and non-ECM components, particularly the matrix metalloproteinases (MMP), a family of proteolytic enzymes that cleave ECM. MMFs have multiple roles in remodeling events that lead to LV dilation. The inhibition or targeted deletion of specific MMPs attenuates LV remodeling events post-MI. MMP inhibitors have been used in animal models to delineate LV remodeling mechanisms and to evaluate the pharmacologic potential of targeting the ECM to modify LV remodeling post-MI. This review summarizes the current knowledge and limitations of MMP inhibition in the post-MI myocardium.

AB - Short-term survival following a myocardial infarction (MI) has greatly improved, due in part to therapeutic interventions that restore blood flow and limit infarct size. The increased incidence of infarct-stimulated left ventricular (LV) remodeling that advances to congestive heart failure (CHF), however, is a significant long-term complication and a leading cause of mortality. Changes to ECM structure and function are primary components of LV remodeling and are precipitated by the early increase in infarct area collagen levels that replace necrotic myocytes and form a scar. ECM turnover is coordinated through the synthesis and degradation of ECM and non-ECM components, particularly the matrix metalloproteinases (MMP), a family of proteolytic enzymes that cleave ECM. MMFs have multiple roles in remodeling events that lead to LV dilation. The inhibition or targeted deletion of specific MMPs attenuates LV remodeling events post-MI. MMP inhibitors have been used in animal models to delineate LV remodeling mechanisms and to evaluate the pharmacologic potential of targeting the ECM to modify LV remodeling post-MI. This review summarizes the current knowledge and limitations of MMP inhibition in the post-MI myocardium.

KW - Extracellular matrix

KW - MMP inhibition

KW - Matrix metalloproteinases

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=1042280329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1042280329&partnerID=8YFLogxK

U2 - 10.1023/B:HREV.0000011390.44039.b7

DO - 10.1023/B:HREV.0000011390.44039.b7

M3 - Review article

C2 - 14739764

AN - SCOPUS:1042280329

VL - 9

SP - 7

EP - 19

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

IS - 1

ER -